MacroGenics Inc. Watch

from 10-Q 6 pages Certain Portions of This Exhibit (Indicated by [***]) Have Been Excluded Pursuant to Item 601(b)(10) of Regulation S-K Because They Are Both Not Material and Are the Type That the Company Customarily and Actually Treats as Private and Confidential

from 10-Q 4 pages This Amendment No. 4 to Global Collaboration and License Agreement (This “Amendment No. 4”) Is Dated as of July 24, 2024, by and Between Incyte Corporation, a Delaware Corporation, Having Its Principal Place of Business at 1801 Augustine Cut-Off, Wilmington, De 19803 (Hereinafter “Incyte”), and Macrogenics, Inc., a Delaware Corporation, Having Its Principal Place of Business at 9704 Medical Center Drive, Rockville, MD 20850 (“Macrogenics”, Together With Incyte, the “Parties” and Each Separately, a “Party”), and Is Meant to Amend That Certain Global Collaboration and License Agreement, Dated as of October 24, 2017, Between Incyte and MacroGenics and Amended on March 15, 2018 (“Amendment No. 1”) and April 7, 2022 (“Amendment No. 2”) and July 14, 2022 (“Amendment No. 3”). the Global Collaboration and License Agreement, Amendment No. 1, Amendment No. 2 and Amendment No. 3 Are Referred to Herein Collectively as the “Agreement.” Capitalized Terms Used and Not Otherwise Defined Herein Shall Have the Meanings Ascribed to Such Terms in the Agreement. Whereas, the Parties Wish to Modify the Agreement to Reflect Changes Agreed to Between the Parties With Respect to (A) the Acceleration of Payment for Certain Milestones With Respect to [***] and (B) the Non-Applicability of Certain Milestones With Respect to [***]; Now, Therefore, in Consideration of the Mutual Covenants Contained Herein, and for Other Good and Valuable Consideration the Receipt and Adequacy of Which Are Hereby Acknowledged, the Parties Agree as Follows: 1. Acceleration of a Development Milestone and Certain Approval Milestones With Respect to the Indication [***]. the Parties Agree That With Respect to the Indication [***]

from 10-Q 6 pages First Amendment to the Collaboration and License Agreement

from 10-K 4 pages Macrogenics, Inc. Rsu Award Grant Notice

from 10-K 5 pages Macrogenics, Inc. Stock Option Grant Notice

from 10-K 4 pages Macrogenics, Inc. Rsu Award Grant Notice

from 10-K 6 pages Macrogenics, Inc. Stock Option Grant Notice

from 10-Q 10 pages Certain Portions of This Exhibit (Indicated by [***]) Have Been Excluded Pursuant to Item 601(b)(10) of Regulation S-K Because They Are Both Not Material and Are the Type That the Company Treats as Private and Confidential. Amendment No. 2 to Asset Purchase Agreement

from 10-Q 41 pages Certain Portions of This Exhibit (Indicated by [***]) Have Been Excluded Pursuant to Item 601(b)(10) of Regulation S-K Because They Are Both Not Material and Are the Type That the Company Treats as Private and Confidential. Purchase and Sale Agreement Dated as of March 8, 2023 Between Macrogenics, Inc. and Dri Healthcare Acquisitions LP

from 10-K 7 pages Fifth Amendment to Lease

from 10-K 8 pages Fourth Amendment to Lease

from 10-K 4 pages Third Amendment to Lease

from 10-K 22 pages Second Amendment to Lease

from 10-K 4 pages First Amendment to Lease

from 10-K 56 pages Agreement

from 10-K 5 pages Certain Portions of This Exhibit (Indicated by [***]) Have Been Excluded Pursuant to Item 601(b)(10) of Regulation S-K Because They Are Both Not Material and Are the Type That the Company Treats as Private and Confidential. Amendment No. 1 to Asset Purchase Agreement

from 10-K 61 pages Asset Purchase Agreement Recitals

from 10-K 140 pages Collaboration and License Agreement Between Macrogenics, Inc. and Gilead Sciences, Inc. Dated October 14, 2022

from 10-Q 3 pages Amendment No. 3 to Global Collaboration and License Agreement

from 10-Q 3 pages Amendment No. 2 to Global Collaboration and License Agreement